SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001104659-23-128307
Filing Date
2023-12-21
Accepted
2023-12-21 17:10:49
Documents
1

Document Format Files

Seq Description Document Type Size
1 DEFA14A tm2333517d2_defa14a.htm DEFA14A 25261
  Complete submission text file 0001104659-23-128307.txt   26323
Mailing Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104
Business Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104 650-808-6000
Theravance Biopharma, Inc. (Filer) CIK: 0001583107 (see all company filings)

IRS No.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-36033 | Film No.: 231506122
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)